Abbott backed Arresto Biosciences in one of its first deals since its corporate venturing unit was set up last year and has now sold the portfolio company to Nasdaq-listed drugs company Gilead Sciences.

Hon Hai commits $15m to Burrage Capital Healthcare Offshore Fund II.

Novartis Venture Fund previously backed Switzerland-based biotechnology company NovImmune that has just raised $21m.

Viscogliosi Brothers lead $15m F round for Small Bone Innovations.

In January, Bloom Health raised $5m in its series A round from BlueCross BlueShield Venture Partners and has now filed after collecting $7.5m for its B stock.

GSK's SR One co-led with venture capital (VC) firm Foundation Medical Partners as new investors in Semprus BioSciences' $18m series B round.

The $14.5m second tranche followed milestones towards clinical trials and came from MedImmune Ventures, a US-based corporate venturing unit of drugs company AstraZeneca, and venture capital firms SV Life Sciences, Advanced Technology Ventures and Clarus Ventures.

Three venture capital firms rather than original backer Boston Scientific provide $20m for US-based medical equipment company TyRx.

Small Bone Innovations (SBI), a US-based orthopedic company treating the small bones and joints, adds Olympus' $12m.